View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 6, 2020

EpiVax partners with UGA researcher on Covid-19 vaccine

EpiVax has partnered with University of Georgia (UGA) researcher Ted Ross for the development of a vaccine against Covid-19 caused by the new coronavirus.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

EpiVax has partnered with University of Georgia (UGA) researcher Ted Ross for the development of a vaccine against Covid-19 caused by the coronavirus.

Ted Ross is a vaccine expert and director of UGA’s Center for Vaccines and Immunology (CVI).

EpiVax developed in silico / computational tools to detect the viral sequence regions that need to be included in vaccines while avoiding sequences linked to less effectiveness or safety.

Previously, the company used its vaccine reengineering approach to Avian influenza (H7N9) under a programme with UGA and UMASS Medical School. The programme receives its funds from the US National Institutes of Health (NIH).

According to EpiVax, rapid analysis and vaccine design were effective for H7N9, expected to aid the Covid-19 vaccine candidate.

EpiVax and the Ross lab have sought more funds from the NIH to support the rapid development of their Covid-19 candidate.

Ross lab had already obtained the novel coronavirus for testing. The new vaccine candidate will be produced and tested at the lab.

In a separate development, Generex Biotechnology entered into a contract with EpiVax to leverage computational tools for identifying epitopes that can produce peptide vaccines against Covid-19.

Generex will also use its NuGenerex Immuno-Oncology Ii-Key technology.

EpiVax has detected multiple ‘hotspots’ in the amino acid sequences of coronavirus proteins.

Generex will now use epitopes predicted by EpiVax to generate a series of synthetic amino acid peptides that can imitate the virus’ epitopes. These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.

The blood samples are expected to contain immune cells and antibodies that will recognise the peptides, proteins and nucleic acids of the virus.

With blood sample testing, the company aims to validate if the predicted sequences will be suitable vaccine peptides.

Last month, Generex signed a contract with four companies in China for the development of an Ii-Key Peptide-based Covid-19 vaccine.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology